BGLC
BioNexus Gene Lab Corp Common stock
NASDAQ: BGLC · BASIC MATERIALS · SPECIALTY CHEMICALS
$2.09
+1.46% today
Updated 2026-04-30
Market cap
$5.37M
P/E ratio
—
P/S ratio
0.72x
EPS (TTM)
$-1.61
Dividend yield
—
52W range
$2 – $16
Volume
0.0M
BioNexus Gene Lab Corp Common stock (BGLC) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | $26.00 | $1.27M | $1.65M | $1.23M | $10.12M | $9.57M | $8.74M | $11.40M | $10.43M |
| Cash & equivalents | $26.00 | $839145.00 | $659235.00 | $859076.00 | $2.79M | $2.12M | $2.12M | $5.93M | $4.38M |
| Current assets | $26.00 | $999718.00 | $1.30M | $882571.00 | $7.99M | $7.08M | $6.02M | $8.05M | $7.43M |
| Total liabilities | $1337.00 | $1.18M | $130313.00 | $108872.00 | $3.45M | $2.39M | $2.08M | $1.74M | $2.11M |
| Current liabilities | $1337.00 | $1.17M | $62893.00 | $51574.00 | $3.37M | $2.33M | $2.00M | $1.63M | $1.95M |
| Long-term debt | — | — | — | — | — | — | — | — | — |
| Shareholder equity | $-1311.00 | $94626.00 | $1.52M | $1.12M | $6.66M | $7.18M | $6.67M | $9.66M | $8.32M |
| Retained earnings | $-1438.00 | $-113296.00 | $-86842.00 | $-333311.00 | $760787.00 | $1.51M | $1.16M | $-1.84M | $-3.44M |
| Accounts receivable | — | $125940.00 | $22814.00 | $2858.00 | $4.00M | $3.36M | $2.90M | $857262.00 | $1.58M |
| Inventory | — | $32086.00 | $15301.00 | $7580.00 | $1.18M | $1.52M | $977807.00 | $1.14M | $1.39M |
| Goodwill | — | — | — | — | — | — | — | — | — |